FDA批准诺华公司治疗2型糖尿病的新药上市
http://www.100md.com
2000年12月27日
NEW YORK (Reuters Health) - Novartis Pharmaceuticals announced on Friday that the US Food and Drug Administration has approved the company's type 2 diabetes drug Starlix (nateglinide).
Starlix, said the East Hanover, New Jersey-based company, restores insulin release, thereby halting the mealtime glucose spikes often experienced by type 2 diabetes patients.
The new drug is indicated for use alone or in combination with metformin, the active ingredient in Bristol-Myers Squibb's diabetes drugs Glucophage and Glucovance, in patients whose blood glucose levels are not controlled by diet and exercise.
Starlix, which was licensed by Novartis from Japan's Ajinomoto, is already approved for use in Japan, Switzerland, Brazil, Mexico and Venezuela.
People with type 2 diabetes lose their sensitivity to insulin, the hormone that regulates blood sugar. The disease usually develops in adulthood and is often related to obesity. About 10 million people have been diagnosed with diabetes in the United States, most of whom have type 2., http://www.100md.com
Starlix, said the East Hanover, New Jersey-based company, restores insulin release, thereby halting the mealtime glucose spikes often experienced by type 2 diabetes patients.
The new drug is indicated for use alone or in combination with metformin, the active ingredient in Bristol-Myers Squibb's diabetes drugs Glucophage and Glucovance, in patients whose blood glucose levels are not controlled by diet and exercise.
Starlix, which was licensed by Novartis from Japan's Ajinomoto, is already approved for use in Japan, Switzerland, Brazil, Mexico and Venezuela.
People with type 2 diabetes lose their sensitivity to insulin, the hormone that regulates blood sugar. The disease usually develops in adulthood and is often related to obesity. About 10 million people have been diagnosed with diabetes in the United States, most of whom have type 2., http://www.100md.com